1 Min Read
Feb 16 (Reuters) - Kalytera Therapeutics Inc:
* Kalytera Therapeutics to announce phase 2A clinical study results investigating cbd for the treatment of acute graft versus host disease Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.